Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Inclusion Criteria: * patients developing breast cancer as confirmed by X-ray examination, cancer tissue negative for estrogen receptor, progesterone receptor and HER2, and tumor stage II-III; * estimated survival \> 3 months; * presence of clinically measurable lesions; * Karnofsky functional status score ≥ 70; * normal routine blood test results, normal liver and kidney function, and near normal electrocardiographic manifestations; * age at 18-70 years. Exclusion Criteria: * stage IV breast cancer patients with bone metastasis or other distant metastasis; * severe renal insufficiency; * older adult patients with severe organic diseases such as heart and lung diseases, who are not estimated to be able to tolerate chemotherapy; * those who have received antineoplastic therapy; * those who have received neoadjuvant chemotherapy but fail in 2 cycles of neoadjuvant chemotherapy and switch to other regimens or terminate chemotherapy; * those with history of other malignant tumors; * those with severe heart, liver, and kidney organ dysfunction or poor health who cannot tolerate chemotherapy, or those who cannot tolerate chemotherapy and switch to other therapeutic regimens; * those with mental and nervous system diseases who cannot comply with treatment; * those with dexamethasone intolerance or those who are highly allergic to any drug in neoadjuvant chemotherapy; * pregnant or lactating women; * those who are participating in other trials.